Santen and RemeGen sign licence deal for retinal disease injection
Santen Pharmaceutical has signed a licensing agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein designed to…
All articles by RanjithKumar Dharma
RanjithKumar Dharma
-
-
Merck announces EC approval of Ogsiveo for desmoid tumours
The European Commission (EC) has granted marketing authorisation to SpringWorks Therapeutics, a subsidiary of Merck KGaA, for Ogsiveo (nirogacestat) to…
-
Aquestive signs $75m agreement for launch of Anaphylm
Aquestive Therapeutics has made a strategic funding agreement worth $75m with RTW Investments to support the potential launch of Anaphylm…
-
FDA approves Tonix’s Tonmya to treat fibromyalgia
Tonix Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Tonmya (cyclobenzaprine HCl sublingual tablets) to…
-
Chugai and Gero link on antibody drugs for age-related conditions
Chugai Pharmaceutical has signed a joint research and licensing agreement with Singapore-based biotechnology firm Gero to create new antibody drug…
-
ProductLife boosts drug development with IntiQuan acquisition
ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics. The move enhances PLG's capabilities…
-
Health Canada approves Telix’s Illuccix label expansion
Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in prostate-specific membrane antigen (PSMA) targeted…
-
OnKure and Reneo Pharmaceuticals complete merger
OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, with the combined entity set to operate under…
-
NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia
Singapore's National University Health System (NUHS) has announced that a new cluster of differentiation (CD7) chimeric antigen receptor (CAR)-T cell…
-
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment specifically targeting…